Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy-Reference-Cited by-同舟云学术

Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy

Published:2020-04-23 Issue:8 Volume:5 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Lipner Matthew B.,Peng Xianlu L.^ORCID,Jin Chong^ORCID,Xu Yi,Gao Yanzhe,East Michael P.,Rashid Naim U.^ORCID,Moffitt Richard A.^ORCID,Herrera Loeza Silvia G.,Morrison Ashley B.,Golitz Brian T.,Vaziri Cyrus,Graves Lee M.,Johnson Gary L.,Yeh Jen Jen^ORCID

Funder

NIH Office of the Director

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/129905/files/pdf

Reference69 articles.

1. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics

2. Cancer statistics, 2018

3. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice;Gebbia;Ann Oncol,2007